An innovative treatment provided by the NHS has shown “groundbreaking” results in putting lupus into remission, as demonstrated by trials conducted in the UK.
In a significant development, individuals with severe lupus in the UK have undergone CAR T-cell therapy for the first time, a treatment that experts believe could also be effective for conditions like multiple sclerosis. This revolutionary therapy, administered only once, has the potential to transform the treatment landscape, potentially eliminating the need for lifelong medication. Katie Tinkler, one of the initial recipients of this treatment, described the impact as a complete transformation in her quality of life.
Lupus is a persistent autoimmune disorder where the immune system mistakenly attacks healthy tissues, leading to widespread inflammation and organ damage, such as in the kidneys, lungs, and heart.
CAR T-cell therapy functions by altering cells genetically to empower the body’s immune system to identify and eliminate problematic cells. Previously limited to cancer patients within the NHS, this therapy has now been trialed in a new NHS study led by University College London Hospitals NHS Foundation Trust (UCLH) and University College London (UCL), resulting in five out of six severe lupus patients achieving remission within a few months of undergoing CAR-T treatment.
Katie Tinkler shared her journey of struggling with severe lupus, which forced her to quit her job due to excruciating pain and fatigue. Following CAR-T treatment at UCLH, she has achieved remission and has seen a drastic improvement in her health and well-being.
Having overcome sepsis, multi-organ failure, and various lupus-related complications, Katie expressed her gratitude for the treatment, highlighting the stark difference in her life before and after the therapy. She has regained the ability to engage in activities that were previously restricted by her condition, including going on a ski trip and dancing at her daughter’s wedding.
By discontinuing all steroid medications and relying only on two daily tablets for blood clot prevention and blood pressure management, Katie described the transformation in her life as miraculous, marking a significant improvement from two years ago.
An estimated 69,000 individuals in the UK are believed to be affected by lupus, predominantly affecting women. The recent study enrolled nine patients with active and severe lupus, demonstrating promising results with CAR-T therapy, indicating a potential “immune reset” rather than mere immune suppression, which is crucial in addressing autoimmune disorders.
Professor Karl Peggs, the director of UCLH’s biomedical research center, emphasized the groundbreaking nature of these findings, offering renewed hope for lupus patients. While further research is warranted, the potential for CAR T-cell therapy to reset the immune system and potentially provide a cure signifies a remarkable advancement in lupus treatment. Larger studies are needed to confirm these results, potentially bringing the prospect of a lupus cure within reach.
